Real-World Evidence Shows Oral INVOKANA ® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news